Purple Biotech Ltd
Company Profile
Business description
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
Contact
4 Oppenheimer Street
Science Park
Rehovot7670104
ISRT: +972 39333121
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
7
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,144.70 | 4.20 | -0.05% |
| CAC 40 | 8,094.20 | 77.27 | -0.95% |
| DAX 40 | 22,999.15 | 288.91 | -1.24% |
| Dow JONES (US) | 41,953.32 | 11.31 | -0.03% |
| FTSE 100 | 8,701.99 | 4.67 | -0.05% |
| HKSE | 24,219.95 | 551.19 | -2.23% |
| NASDAQ | 17,691.63 | 59.16 | -0.33% |
| Nikkei 225 | 37,751.88 | 93.54 | -0.25% |
| NZX 50 Index | 12,113.27 | 58.55 | 0.49% |
| S&P 500 | 5,662.89 | 12.40 | -0.22% |
| S&P/ASX 200 | 7,917.50 | 1.40 | -0.02% |
| SSE Composite Index | 3,408.95 | 17.48 | -0.51% |